$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H1 2017
[Lowest Price Guaranteed: $3,500]

Published by Global Markets Direct: 30 May 2017 | 75276 | In Stock
Related Topics: Alzheimer's Disease , Bladder Cancer , Breast Cancer , Cancer , Cirrhosis , Colorectal Cancer , Gas , Hepatitis , Hypertension , Immunology , Infectious Disease , Lung Cancer , Multiple Myeloma , Myeloma , Ophthalmology , Pancreatic Cancer , Parkinson's Disease , Prostate Cancer , Protein , Pulmonary , Respiratory , Steatohepatitis

Introduction

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H1 2017

Summary

According to the recently published report 'Caspase 3 - Pipeline Review, H1 2017'; Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Caspase-3 is a caspase protein encoded by the CASP3 gene. It interacts with caspase-8 and caspase-9. It cleaves and activates sterol regulatory element binding proteins (SREBPs) between the basic helix-loop-helix leucine zipper domain and the membrane attachment domain. It cleaves and activates caspase-6, -7 and -9. It is involved in the cleavage of huntingtin. It triggers cell adhesion in sympathetic neurons through RET cleavage

The report 'Caspase 3 - Pipeline Review, H1 2017' outlays comprehensive information on the Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Genito Urinary System And Sex Hormones, Cardiovascular, Central Nervous System, Infectious Disease, Hematological Disorders, Immunology, Metabolic Disorders, Ophthalmology, Respiratory and Toxicology which include indications Prostate Cancer, Colorectal Cancer, Glomerulonephritis, Inflammatory Bowel Disease, Age Related Macular Degeneration, Alzheimer's Disease, Autoimmune Hepatitis, Bladder Cancer, Breast Cancer, Chemotherapy Induced Neutropenia, Diabetic Retinopathy, Febrile Neutropenia, Glioblastoma Multiforme (GBM), Hepatitis C, Hepatocellular Carcinoma, Huntington Disease, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Transplant Rejection, Metastatic Brain Tumor, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Myocardial Infarction, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Parkinson's Disease, Portal Hypertension, Primary Sclerosing Cholangitis, Pulmonary Fibrosis, Renal Failure, Solid Tumor, Spinal Cord Injury, Stroke, Traumatic Brain Injury, Urinary Tract Cancer and Zika Virus Infections.

Scope

- The report provides a snapshot of the global therapeutic landscape for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)

- The report reviews Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)targeted therapeutics and enlists all their major and minor projects

- The report assesses Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H1 2017

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Overview

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Companies Involved in Therapeutics Development

    Aptose Biosciences Inc

    BeyondSpring Pharmaceuticals Inc

    Conatus Pharmaceuticals Inc

    New World Laboratories Inc

    Pharmedartis GmbH

    Sanofi

    Shire Plc

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Drug Profiles

    1G3-Cu - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BaxB-01 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BaxG-03 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BaxM-159 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    emricasan - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    emricasan - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    flavokawain A - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    HaA-4 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    IDN-7314 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NWL-53 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    plinabulin - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Recombinant Protein to Activate CASP3 and CASP9 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Recombinant Protein to Activate Caspases for Diabetic Retinopathy, Age Related Macular Degeneration and Solid Tumor - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Activate Caspase-3 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Activate Caspase 3 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Dormant Products

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Discontinued Products

    Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Product Development Milestones

    Featured News & Press Releases

    May 08, 2017: BeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences in May 2017

    Apr 25, 2017: BeyondSpring Enrolls First US Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention

    Mar 22, 2017: BeyondSpring Chief Medical Officer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017

    Mar 20, 2017: BeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British Columbia

    Mar 14, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in Tokyo

    Feb 23, 2017: BeyondSpring Clinical Data for Lead Asset, Plinabulin, Accepted for Oral Presentation at IASLC's 2017 Targeted Therapies of the Treatment of Lung Cancer

    Feb 21, 2017: BeyondSprings Promising Clinical Data for Lead Asset on Non-Small Cell Lung Cancer Treatment Selected for Presentation at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

    Jan 24, 2017: FDA Accepts BeyondSpring IND Application for Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia

    Jan 10, 2017: BeyondSpring to Present at Biotech Showcase 2017 During Annual JPMorgan Healthcare Conference on January 10 in San Francisco

    Dec 19, 2016: BeyondSpring Presents Encouraging Clinical Data for Lead Asset on Chemotherapy-Induced Neutropenia at 2016 ASH Annual Meeting

    Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting

    Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis

    Nov 03, 2016: BeyondSpring Clinical Data on Neutropenia Mitigation with Plinabulin to be Presented at 2016 ASH Annual Meeting

    Oct 03, 2016: Conatus Pharmaceuticals Announces Acceptance of Emricasan Abstracts for AASLD Annual Meeting

    Sep 27, 2016: BeyondSpring Announces First Patient Enrolled in Phase 1b/2 Investigator-Initiated Trial of Plinabulin plus Nivolumab for Non-Small Cell Lung Cancer

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

75276 | GMDHC0784TDB

Number of Pages

77

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H1 2018
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic ...
27 Feb 2018 by Global Markets Direct USD $3,500 More Info
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2017
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 ...
31 Oct 2017 by Global Markets Direct USD $3,500 More Info
Caspase 3 (CPP32, Apopain or YAMA) Activators -Pipeline Insights, 2017
DelveInsight’s, “Caspase 3 (CPP32, Apopain or YAMA) Activators-Mechanism of action Insights, 2017”, ...
01 Sep 2017 by Delve Insight USD $1,250 More Info
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2017
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic ...
29 Aug 2017 by Global Markets Direct USD $3,500 More Info
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2017
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ce...
18 Jul 2017 by Global Markets Direct USD $3,500 More Info
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2017
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2017SummaryAccor...
20 Jun 2017 by Global Markets Direct USD $3,500 More Info
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H1 2017
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22....
13 Jun 2017 by Global Markets Direct USD $3,500 More Info
Caspase 3 (CPP32, Apopain or YAMA) Activators -Pipeline Insights, 2017
DelveInsight’s, “Caspase 3 (CPP32, Apopain or YAMA) Activators-Pipeline Insights, 2017”, report prov...
30 May 2017 by Delve Insight USD $1,250 More Info
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2016
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ce...
21 Dec 2016 by Global Markets Direct USD $3,500 More Info
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2016
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic ...
16 Nov 2016 by Global Markets Direct USD $3,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H1 2017 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...